About Tubulin epsilon and delta complex protein 2
Tubulin epsilon and delta complex protein 2 (TEDC2) is a protein
from Homo sapiens identified by UniProt accession
Q7L2K0, 433 residues long.
MolForge cross-references it against 0 known binders and
30 disease associations.
Target properties
| Protein name | Tubulin epsilon and delta complex protein 2 |
| UniProt accession | Q7L2K0 |
| Gene | TEDC2 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (30)
Diseases linked to this target (Open Targets).
- lung adenocarcinoma · score 0.08
- neoplasm · score 0.08
- Griscelli syndrome type 3 · score 0.05
- hepatocellular carcinoma · score 0.05
- uncombable hair syndrome · score 0.04
- Griscelli disease type 3 · score 0.04
- Griscelli disease · score 0.04
- oculocutaneous albinism type 3 · score 0.04
- Griscelli disease type 1 · score 0.04
- non-small cell lung carcinoma · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q7L2K0-F1 | alphafold | PREDICTED | 67.10 | — |
Amino-acid sequence (433 residues)
MLPAGCSRRL VAELQGALDA CAQRQLQLEQ SLRVCRRLLH AWEPTGTRAL KPPPGPETNG EDPLPACTPS PQDLKELEFL TQALEKAVRV RRGITKAGER DKAPSLKSRS IVTSSGTTAS APPHSPGQAG GHASDTRPTK GLRQTTVPAK GHPERRLLSV GDGTRVGMGA RTPRPGAGLR DQQMAPSAAP QAPEAFTLKE KGHLLRLPAA FRKAASQNSS LWAQLSSTQT SDSTDAAAAK TQFLQNMQTA SGGPQPRLSA VEVEAEAGRL RKACSLLRLR MREELSAAPM DWMQEYRCLL TLEGLQAMVG QCLHRLQELR AAVAEQPPRP CPVGRPPGAS PSCGGRAEPA WSPQLLVYSS TQELQTLAAL KLRVAVLDQQ IHLEKVLMAE LLPLVSAAQP QGPPWLALCR AVHSLLCEGG ARVLTILRDE PAV
Explore Tubulin epsilon and delta complex protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets